{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["119"],"submitter":["Schumacher JG"],"funding":["National Institute of Neurological Disorders and Stroke","Aligning Science Across Parkinson&apos;s","Michael J. Fox Foundation for Parkinson&apos;s Research"],"pubmed_abstract":["<h4>Background</h4>α-Synuclein (α-syn) seed amplification assays (SAAs) have shown remarkable potential in diagnosing Parkinson's disease (PD). Using data from the Parkinson's Progression Markers Initiative (PPMI) cohort, we aimed to test whether baseline α-syn seeding activity and α-syn SAA kinetic parameters are associated with disease progression in sporadic PD, LRRK2-associated PD (LRRK2 PD), and GBA-associated PD (GBA PD).<h4>Methods</h4>We analysed 7 years of motor, non-motor, and cognitive assessments and 5 years of dopamine transporter imaging along with baseline α-syn SAA results from 564 PPMI participants (n = 332 sporadic PD, 162 LRRK2 PD, and 70 GBA PD) using linear mixed-effects models, adjusted for potential confounders, to test whether baseline α-syn SAA positivity (n = 315 "],"journal":["EBioMedicine"],"pagination":["105866"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12354789"],"repository":["biostudies-literature"],"pubmed_title":["Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort."],"pmcid":["PMC12354789"],"pubmed_authors":["Schwarzschild MA","Zhang X","Watanabe H","Dijkstra JM","Schumacher JG","Chen X","Bayati A","Wang J","Macklin EA","Cortese M"],"additional_accession":[]},"is_claimable":false,"name":"Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort.","description":"<h4>Background</h4>α-Synuclein (α-syn) seed amplification assays (SAAs) have shown remarkable potential in diagnosing Parkinson's disease (PD). Using data from the Parkinson's Progression Markers Initiative (PPMI) cohort, we aimed to test whether baseline α-syn seeding activity and α-syn SAA kinetic parameters are associated with disease progression in sporadic PD, LRRK2-associated PD (LRRK2 PD), and GBA-associated PD (GBA PD).<h4>Methods</h4>We analysed 7 years of motor, non-motor, and cognitive assessments and 5 years of dopamine transporter imaging along with baseline α-syn SAA results from 564 PPMI participants (n = 332 sporadic PD, 162 LRRK2 PD, and 70 GBA PD) using linear mixed-effects models, adjusted for potential confounders, to test whether baseline α-syn SAA positivity (n = 315 ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-18T11:21:25.428Z","creation":"2026-04-07T14:35:39.848Z"},"accession":"S-EPMC12354789","cross_references":{"pubmed":["40773926"],"doi":["10.1016/j.ebiom.2025.105866"]}}